Article
Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing.
International journal of cancer - 1 Nov 2025
Peeters Sofía L J, Meulendijks Didier, Kadric Zerina, Ibrovic Sara, Creemers Geert-Jan, Milosevic Vanja, van de Poll Matthijs, Simkens Lieke H J, Deiman Birgit A L M, Gelderblom Hans, Guchelaar Henk-Jan, Thijs Anna M J, Deenen Maarten J
Abstract excerpt
DPYD gene variations are associated with severe fluoropyrimidine toxicity, and an initial 50% dose reduction is widely recommended for heterozygous carriers of relevant DPYD variants, including DPYD*2A, DPYD*13, c.2846A>T, and c.1236G>A. However, there is a high variability in DPD activity between DPYD variant carriers, and a proportion of patients may tolerate higher fluoropyrimidine doses. The aim of this...
Topics
Join the communities discussing this publication.